Mostra filtri
Tipo di risorse
Filtra per Tipo di risorse
Patologie
Filtra per Patologie
Tecnologie
Filtra per Tecnologie
Strumenti
Filtra per Strumenti
86 Risultato/i trovato/i
Ordina per:

Unlocking the power of anti-MCV detection for early diagnosis of Rheumatoid Arthritis

Webinar
Giu. 07, 2024

Educational Workshop with Holger Bang, PhD & Roberto Fiorillo

Mag. 17, 2024 Mag. 20, 2024

Evento
Ljubljana, Slovenia

14th International Congress on Autoimmunity 2024

Sebia booth #15

Scopri di più

Sebia receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices

Comunicato stampa
Apr. 11, 2024

The next generation instrument for screening hemoglobin disorders in newborns.

Apr. 18, 2024 Apr. 20, 2024

Evento
Torino, Italy

European Myeloma Network Meeting – EMN 2024

Sebia booth: #9

Scopri di più

Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays

Comunicato stampa
Mar. 07, 2024

Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.

How External Quality Assessment supports quality improvement in laboratory hemoglobinopathy diagnosis

Webinar
Feb. 20, 2024

Educational Workshop with Dr. Barbara De la Salle

HYDRASYS 2 SCAN FOCUSING: Overview

Video
Feb. 13, 2024

Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.

Sebia launches M-inSight®, a test for monitoring multiple myeloma patients

Comunicato stampa
Dic. 04, 2023

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma